Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection

Bosteels, Cédric; Neyt, Katrijn; Vanheerswynghels, Manon; Helden, Mary J. van; Sichien, Dorine; Debeuf, Nincy; Prijck, Sofie De; Bosteels, Victor; Vandamme, Niels; Martens, Liesbet; Saeys, Yvan; Louagie, Els; Lesage, Manon; Williams, David L.; Tang, Shiau-Choot; Mayer, Johannes U; Ronchese, Franca; Scott, Charlotte; Hammad, Hamida; Guilliams, Martin; Lambrecht, Bart N.

doi:10.1016/j.immuni.2020.04.005

Cited by 293 publications

(393 citation statements)

References 107 publications

(169 reference statements)

Supporting

Mentioning

369

Contrasting

Unclassified

Order By: Relevance

“…Recently, Bosteels et al have shown that in the mouse lung CD26 + CD172 + DC2s in response to type I interferon can up-regulate IRF8 and CD64 and acquire features of both DC1s and monocytes (91). This suggests that there is further complexity of dendritic cells in inflammation, and it stresses the necessity to carefully delineate DC subsets in disease settings, where such inflammatory DC2s increase.…”

Section: Dc2 Subsets In the Mouse In Lungmentioning

confidence: 99%

Subsets of CD1c+ DCs: Dendritic Cell Versus Monocyte Lineage

Heger

Hofer²,

Bigley

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Currently three bona fide dendritic cell (DC) types are distinguished in human blood. Herein we focus on type 2 DCs (DC2s) and compare the three defining markers CD1c, CD172, and CD301. When using CD1c to define DC2s, a CD14 + and a CD14 − subset can be detected. The CD14 + subset shares features with monocytes, and this includes substantially higher expression levels for CD64, CD115, CD163, and S100A8/9. We review the current knowledge of these CD1c + CD14 + cells as compared to the CD1c + CD14 − cells with respect to phenotype, function, transcriptomics, and ontogeny. Here, we discuss informative mutations, which suggest that two populations have different developmental requirements. In addition, we cover subsets of CD11c + CD8 − DC2s in the mouse, where CLEC12A + ESAM low cells, as compared to the CLEC12A − ESAM high subset, also express higher levels of monocyte-associated markers CD14, CD3, and CD115. Finally, we summarize, for both man and mouse, the data on lower antigen presentation and higher cytokine production in the monocytemarker expressing DC2 subset, which demonstrate that the DC2 subsets are also functionally distinct.

show abstract

Section: Dc2 Subsets In the Mouse In Lungmentioning

confidence: 99%

Subsets of CD1c+ DCs: Dendritic Cell Versus Monocyte Lineage

Heger

Hofer²,

Bigley

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…67 Intriguingly, inf-cDC2 can acquire cDC1 characteristics in a type-I-IFN-dependent manner and become capable of optimally priming CD4 + and CD8 + T cells. 67 The infected lung also contains moDC, which are non-migratory and are poor activators of CD4 + or CD8 + T cells, compared with cDC. 67 Additionally, lung pDC can produce large amounts of type-I-IFN in response to infection with pneumonia virus of mice, inducing a proinflammatory antiviral response.…”

Section: Myeloid Apc In Cbt-sensitive Carcinomasmentioning

confidence: 99%

“…67 The infected lung also contains moDC, which are non-migratory and are poor activators of CD4 + or CD8 + T cells, compared with cDC. 67 Additionally, lung pDC can produce large amounts of type-I-IFN in response to infection with pneumonia virus of mice, inducing a proinflammatory antiviral response. 68 Although the immune-stimulatory potential of lung DC can have protective effects in cancer, the lung TME inhibits their antitumor functions (figure 2), and efforts are underway to test the efficacy of combining a DC-based vaccine with CBT.…”

Section: Myeloid Apc In Cbt-sensitive Carcinomasmentioning

confidence: 99%

Impact of anatomic site on antigen-presenting cells in cancer

Zagorulya

Duong

Spranger

2020

J Immunother Cancer

View full text Add to dashboard Cite

Checkpoint blockade immunotherapy (CBT) can induce long-term clinical benefits in patients with advanced cancer; however, response rates to CBT vary by cancer type. Cancers of the skin, lung, and kidney are largely responsive to CBT, while cancers of the pancreas, ovary, breast, and metastatic lesions to the liver respond poorly. The impact of tissue-resident immune cells on antitumor immunity is an emerging area of investigation. Recent evidence indicates that antitumor immune responses and efficacy of CBT depend on the tissue site of the tumor lesion. As myeloid cells are predominantly tissue-resident and can shape tumor-reactive T cell responses, it is conceivable that tissue-specific differences in their function underlie the tissue-site-dependent variability in CBT responses. Understanding the roles of tissue-specific myeloid cells in antitumor immunity can open new avenues for treatment design. In this review, we discuss the roles of tissue-specific antigen-presenting cells (APCs) in governing antitumor immune responses, with a particular focus on the contributions of tissue-specific dendritic cells. Using the framework of the Cancer-Immunity Cycle, we examine the contributions of tissue-specific APC in CBT-sensitive and CBT-resistant carcinomas, highlight how these cells can be therapeutically modulated, and identify gaps in knowledge that remain to be addressed.

show abstract

“…In vitro differentiated DCs from monocytes (MoDCs) are a broadly accepted model, nevertheless, it has been reported that they functionality could be affected by the treatments used in order to differentiate them (9,(19)(20)(21). Moreover, MoDC are different cells from conventional DC (cDCs) (22) that differentiate in peripheral tissues only in inflammatory conditions, and they do not migrate in the lymph or do it weakly (23) while ALDC are mainly cDC. Charleston and collaborators (9) have developed a technique to cannulate bovine afferent lymphatic vessels, allowing collecting of large volumes of lymph containing afferent lymph dendritic cells (ALDCs).…”

Section: Discussionmentioning

confidence: 99%